As of May 22
| +0.49 / +0.44%|
The 21 analysts offering 12-month price forecasts for Gilead Sciences have a median target of 123.00, with a high estimate of 159.00 and a low estimate of 84.00. The median estimate represents a +10.11% increase from the last price of 111.71.
The current consensus among 26 polled investment analysts is to Buy stock in Gilead Sciences. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.